Everolimus-eluting bioresorbable vascular scaffold in patients with coronary artery disease

Trial Profile

Everolimus-eluting bioresorbable vascular scaffold in patients with coronary artery disease

Planning
Phase of Trial: Phase III

Latest Information Update: 17 Jan 2011

At a glance

  • Drugs Everolimus (Primary)
  • Indications Coronary artery disease; Coronary artery restenosis
  • Focus Therapeutic Use
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 17 Jan 2011 New trial record
    • 10 Jan 2011 The global trial, including the USA and other locations, is planned for later this year, according to an Abbott media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top